Calamos Advisors’s Oramed Pharmaceuticals ORMP Stock Holding History

Calamos Advisors’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-14,746	Closed	-$177K	–	1192
2022 Q4	$177K	Buy	+14,746	New	+$115K	﹤0.01%	953
2022 Q2	–	Sell	-38,071	Closed	-$330K	–	1196
2022 Q1	$330K	Sell	38,071 -73,448	-66%	-$752K	﹤0.01%	1102
2021 Q4	$1.59M	Sell	111,519 -20,626	-16%	-$431K	0.01%	934
2021 Q3	$2.91M	Buy	+132,145	New	+$2.25M	0.01%	726

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

SIGI

Susquehanna International Group (Ireland) Dublin, Ireland $472M AUM 25.62% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Calamos Advisors's ORMP Position: Q1 2023 in Review

Calamos Advisors sold out of Oramed Pharmaceuticals (ORMP) in Q1 2023, closing a stake of 14,746 shares — an estimated $177K sold.

Calamos Advisors first reported a position in ORMP in Q3 2021 and held it in 4 quarters. The position peaked at $2.91M in Q3 2021. 61 funds tracked by Wall St. Rank hold ORMP as of Q1 2023.

Calamos Advisors reported no remaining Oramed Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Calamos Advisors sold 14,746 Oramed Pharmaceuticals shares in Q1 2023, an estimated $177K.
Calamos Advisors first reported a position in Oramed Pharmaceuticals in Q3 2021 and held it in 4 quarters.
Calamos Advisors's Oramed Pharmaceuticals position peaked at $2.91M in Q3 2021.
61 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2023.

Based on Calamos Advisors's 13F filing for Q1 2023, filed 4 May 2023.